A Linker Platform For Antibody Drug Conjugates: Expanding The Therapeutic Window
- Baylink's novel linkers enable use of hydrophobic drugs at high DAR, and can reduce off-target effectsÂ
- It expands the diversity of payloads, including chemotherapy, protein degraders, and immunotherapy
- The lead candidate will enter phase I clinical trial in 2026